inThought Research, Inc.: inThought and inThought Labs Announce AI Initiative: Cut Down Tedious Tasks
ORLANDO, Fla., Sept. 24, 2024 /PRNewswire/ — inThought Research Inc., a leading provider of decision support for the life sciences industry, has unveiled its artificial intelligence (AI) strategy. This strategy leverages machine learning and large language models to minimize tedious tasks in a compliant and secure manner, providing substantial support to partners in the drug discovery industry.
With vast amounts of data and opinions readily available, decision-makers in all sectors face challenges in identifying the most relevant information and insights. inThought Labs, the technology division of inThought, collaborates with drug makers to develop both human intelligence and AI solutions. The objective is to elevate daily tasks from merely sorting information to genuine insight generation and decision-making.
Current AI-Based Solutions
inThought Labs currently offers several AI-driven solutions to streamline and enhance processes, including:
- Machine Learning Driven Screening: This tool monitors changes in clinicaltrials.gov, helping inThought analysts and clients track significant updates based on indications, compound names, or other keywords. The system learns what’s important to each user over time, highlighting critical trials, ranking others based on relevance, and suggesting ignored ones. The ranking system improves continuously with user feedback.
- Generative AI Summaries: This service provides concise summaries of medical conference abstracts, enabling teams to quickly review poster and oral presentations.
- Text Extraction and Summarization: This feature extracts and summarizes content from conference slides and posters. Summaries of figures and graphs are slated for future releases.
- Integration with inVision: The Generative AI capabilities are integrated directly into the inVision system, allowing users to promptly and securely summarize press releases, earnings reports, conference notes, and other important content.
inThought invites its partners to collaborate on developing new AI-based solutions aimed at reducing tedious tasks. Their team of AI experts understands the regulatory and confidentiality challenges unique to the pharmaceutical, biotech, and AI development landscapes. The inVision platform is SOC2 compliant, ensuring high standards of data security and privacy.
For more information, please visit www.inthought.com/ai and www.inthoughtlabs.com/ai.
About inThought
inThought Research empowers biopharma leaders with comprehensive strategic insights. The company combines Wall Street financial acumen and swiftness, scientific and medical expertise, and advanced AI analytics to help navigate the complex landscape of drug development. Their multidisciplinary approach integrates clinical data, market analytics, and stakeholder perspectives. Through inThought Labs, they merge cutting-edge technology with their subject matter experts’ efforts to transform complex data into actionable intelligence. For further information, please visit www.inthought.com.
Contact Information
Adam Schaeffer, MBA, Chief Business Officer
301.515.8262
aschaeffer@inthought.com
© 2024 PR Newswire
